I agree that the dosing follows smoothly after the enrollment process. I also agree that the data may be available earlier than March 31. I suspect enrollment will be rapid in all 3 trials. There is an enormous unmet need in all 3 indications. However there is usually a period of data analysis before results are made public. I think Q2 of 2019 will be very interesting.